Document Detail


T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
MedLine Citation:
PMID:  23549607     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy (HCM) and a potential substrate for arrhythmias and heart failure. Sarcomere mutations seem to induce profibrotic changes before left ventricular hypertrophy (LVH) develops. To further evaluate these processes, we used cardiac magnetic resonance with T1 measurements on a genotyped HCM population to quantify myocardial extracellular volume (ECV).
METHODS AND RESULTS: Sarcomere mutation carriers with LVH (G+/LVH+, n=37) and without LVH (G+/LVH-, n=29), patients with HCM without mutations (sarcomere-negative HCM, n=11), and healthy controls (n=11) underwent contrast cardiac magnetic resonance, measuring T1 times pre- and postgadolinium infusion. Concurrent echocardiography and serum biomarkers of collagen synthesis, hemodynamic stress, and myocardial injury were also available in a subset. Compared with controls, ECV was increased in patients with overt HCM, as well as G+/LVH- mutation carriers (ECV=0.36±0.01, 0.33±0.01, 0.27±0.01 in G+/LVH+, G+/LVH-, controls, respectively; P≤0.001 for all comparisons). ECV correlated with N-terminal probrain natriuretic peptide levels (r=0.58; P<0.001) and global E' velocity (r=-0.48; P<0.001). Late gadolinium enhancement was present in >60% of overt patients with HCM but absent from G+/LVH- subjects. Both ECV and late gadolinium enhancement were more extensive in sarcomeric HCM than sarcomere-negative HCM.
CONCLUSIONS: Myocardial ECV is increased in HCM sarcomere mutation carriers even in the absence of LVH. These data provide additional support that fibrotic remodeling is triggered early in disease pathogenesis. Quantifying ECV may help characterize the development of myocardial fibrosis in HCM and ultimately assist in developing novel disease-modifying therapy, targeting interstitial fibrosis.
Authors:
Carolyn Y Ho; Siddique A Abbasi; Tomas G Neilan; Ravi V Shah; Yucheng Chen; Bobak Heydari; Allison L Cirino; Neal K Lakdawala; E John Orav; Arantxa González; Begoña López; Javier Díez; Michael Jerosch-Herold; Raymond Y Kwong
Related Documents :
9604957 - Prevalence and effects of cardiac rehabilitation on depression in the elderly with coro...
24001037 - Accumulation of epicardial fat rather than visceral fat is an independent risk factor f...
24814007 - Effects of paclitaxel and carboplatin combination on mechanical myocardial and microvas...
23070737 - Mapping contrast agent uptake and retention in mri studies of myocardial perfusion: cas...
2566107 - Lipids and lipoproteins in patients undergoing coronary-artery surgery.
12939547 - Osteopontin is released from the heart into the coronary circulation in patients with a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-04-02
Journal Detail:
Title:  Circulation. Cardiovascular imaging     Volume:  6     ISSN:  1942-0080     ISO Abbreviation:  Circ Cardiovasc Imaging     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-22     Completed Date:  2013-07-18     Revised Date:  2014-05-07    
Medline Journal Info:
Nlm Unique ID:  101479935     Medline TA:  Circ Cardiovasc Imaging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  415-22     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Analysis of Variance
Biological Markers / blood
Cardiomyopathy, Hypertrophic / blood,  diagnosis*,  genetics,  pathology,  physiopathology
Case-Control Studies
Collagen / blood
Contrast Media / diagnostic use
DNA Mutational Analysis
Disease Progression
Extracellular Matrix / metabolism,  pathology*
Female
Fibrosis
Gadolinium DTPA / diagnostic use
Genetic Predisposition to Disease
Hemodynamics
Humans
Hypertrophy, Left Ventricular / blood,  diagnosis*,  genetics,  pathology,  physiopathology
Logistic Models
Magnetic Resonance Imaging, Cine*
Male
Middle Aged
Mutation*
Myocardium / metabolism,  pathology*
Phenotype
Predictive Value of Tests
Prognosis
Sarcomeres / metabolism,  pathology*
Ventricular Remodeling* / genetics
Young Adult
Grant Support
ID/Acronym/Agency:
P20 HL101408/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Contrast Media; 9007-34-5/Collagen; K2I13DR72L/Gadolinium DTPA
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanochemical preparation of co-crystals.
Next Document:  Genetic background of nonmutant Piebald-Virol-Glaxo rats does not influence nephronophthisis phenoty...